ADC

5개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved5 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCCurated CoreFDAstaleGenmabApproved

Tisotumab Vedotin (Tisotumab Vedotin)

Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung · Solid Malignancies

#SolidMalignancies#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 14Status Approved
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Neurokinin-1 receptor antagonist (Neurokinin-1 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 45Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCDeruxtecan in Patients With…Phase 2

I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd))

Carcinoma, Non-Small-Cell Lung · Small-Cell Lung Cancer

#Small-CellLungCancer#ADC#Phase2#antibody-drug-conjugate#Carcinoma+4
Trials 41Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Raludotatug deruxtecan (Raludotatug deruxtecan)

Carcinoma, Non-Small-Cell Lung · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 7Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

5-hydroxytryptamine subtype 3 receptor antagonist (5-hydroxytryptamine subtype 3 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 4Status Recruiting